Critical dose drugs [Regulatives / Guidelines]

posted by suchit_bhavsar – India, 2017-04-24 14:04 (2849 d 09:45 ago) – Posting: # 17257
Views: 3,534

❝ If you aimed for a submission in Canada I think the

❝ "Guidance Document - Comparative Bioavailability Standards: Formulations Used for Systemic Effects" paragraph 2.1.1.6 Critical dose drugs applies.


Thnx a lot for your reply.
As per "Guidance Document - Comparative Bioavailability Standards: Formulations Used for Systemic Effects" paragraph 2.1.1.6 Critical dose drugs gives criteria of NTI drugs.
Actually for molecule like rivaroxaban(Anticoagulant) its OGD says that,
Applicants should use the average BE approach with BE limits of 80-125%. The within-subject variability of test (T) and reference (R) products should be compared, and the upper limit of the 90% confidence interval for the test-to-reference ratio of the within-subject variability should be ≤ 2.5.

So, should i use "Guidance Document - Comparative Bioavailability Standards: Formulations Used for Systemic Effects" paragraph 2.1.1.6 Critical dose drugs?:-)

Regards,
Nirav


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,379 posts in 4,913 threads, 1,661 registered users;
256 visitors (0 registered, 256 guests [including 23 identified bots]).
Forum time: 22:49 CET (Europe/Vienna)

Science is what you know.
Philosophy is what you don’t know.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5